AP NEWS
Click to copy
Press release content from Business Wire. The AP news staff was not involved in its creation.
Click to copy
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Global CTLA4 (Cytotoxic T-Lymphocyte-Associated Protein 4) Inhibitors Market Forecast & Analysis Report (2019-2023) - ResearchAndMarkets.com

September 10, 2019

DUBLIN--(BUSINESS WIRE)--Sep 10, 2019--

The “CTLA4 (Cytotoxic T-Lymphocyte-Associated Protein 4) Inhibitors Market by Type and Geography - Global Forecast and Analysis 2019-2023” report has been added to ResearchAndMarkets.com’s offering.

The CTLA4 (Cytotoxic T-Lymphocyte-Alymphocyte-associated Protein 4) inhibitors market analysis considers sales from both monotherapy and combination therapy. The analysis also considers the sales of CTLA4 (Cytotoxic T-Lymphocyte-Associated Protein 4) inhibitors in Asia, Europe, North America, and RoW.

In 2018, the monotherapy segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as low side effects and better tolerability will play a significant role in the monotherapy segment to maintain its market position.

Also, the global CTLA4 inhibitors market report looks at factors such as high target affinity and specificity of CTLA4 inhibitors, growing popularity of combination therapy, and strategic alliances. However, lack of approved therapies, availability of substitutes, and stringent regulations may hamper the growth of the CTLA4 (Cytotoxic T-Lymphocyte-Alymphocyte-associated Protein 4) inhibitors industry over the forecast period.

High target affinity and specificity of CTLA4 inhibitors

CTLA4 inhibitors function by boosting the immune system and reducing the side effects. CTLA-4 is a protein found on the surface of T-cells which suppress the growth of cancer cells by activating the immune system. These drugs work directly on the target, and their efficacy is higher than that of other conventional treatments such as chemotherapy.

Though the CTLA4 inhibitors are new to the oncology treatment landscape, increasing R&D efforts by market vendors are supporting the growth of CTLA4 inhibitors market. This will lead to the expansion of the global CTLA4 inhibitors market at a CAGR of over 9% during the forecast period.

Increasing awareness about cancer

The awareness programs conducted by various organizations provide an opportunity to raise awareness about lung cancer screening and treatment options, including CTLA4 inhibitors. For instance, Cancer Breakthroughs 2020 an initiative taken by the US government for the development of research on vaccine-based immunotherapies for cancer.

This project aimed at making therapies available to more patients while detecting the disease at an early stage. Such awareness programs are also raising awareness about the treatment of various cancer types by using CTLA4 inhibitors. This development is expected to have a positive impact on the overall market growth.

Competitive Landscape

With the presence of a few major players, the global CTLA4 inhibitors market is highly concentrated. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of few leading CTLA4 inhibitors manufacturers, that include:

Also, the CTLA4 (Cytotoxic T-Lymphocyte-Alymphocyte-associated Protein 4) inhibitors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

Key Topics Covered

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

PART 04: MARKET SIZING

PART 05: FIVE FORCES ANALYSIS

PART 06: MARKET SEGMENTATION BY TYPE

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE

PART 13: VENDOR ANALYSIS

For more information about this report visit https://www.researchandmarkets.com/r/iwykua

View source version on businesswire.com:https://www.businesswire.com/news/home/20190910005754/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 09/10/2019 10:17 AM/DISC: 09/10/2019 10:17 AM

http://www.businesswire.com/news/home/20190910005754/en

All contents © copyright 2019 The Associated Press. All rights reserved.